Moderna, Inc. announced in May 2024 that the FDA approved mRESVIA™, an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna, both of which are based on intellectual property developed at Penn by Drs. Drew Weissman, MD, PhD, the Roberts Family Professor of Vaccine Research and Katalin Karikó, PhD, an Adjunct Professor of Neurosurgery at Penn Medicine. RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia that causes a particularly large burden of disease in infants and older adults. Read more here.